13 June 2016 - A charity has said it is "grossly unfair" that men with advanced prostate cancer in Scotland will not be able to get a treatment on the NHS that could extend their lives.

The SMC has rejected cabazitaxel chemotherapy for routine use by the NHS.

It has been approved for use in England and Wales by the National Institute for Health and Care Excellence (NICE).

Prostate Cancer UK said the decision was "baffling".

SMC chairman Prof Jonathan Fox said: "Unfortunately, the committee was not able to recommend cabazitaxel for prostate cancer as the overall health benefits offered by the medicine did not justify its cost.

"Discussions around next steps have been held between SMC and the company, and we would welcome a resubmission reflecting the points raised in our assessment."

For more details, go to: http://www.bbc.com/news/uk-scotland-36522259